Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

Corundum Convergence Institute Funds MIT Project to Research Algorithmic Solutions Addressing Causes of Neurodegeneration in Aging Humans


News provided by

Corundum Convergence Institute

04 Feb, 2025, 16:44 IST

Share this article

Share toX

Share this article

Share toX

 Project Aims to Harness Sleep-Dependent Sensory Stimulation to Enhance Cerebrospinal Fluid Flow in the Brain

CAMBRIDGE, Mass.  , Feb. 4, 2025 /PRNewswire/ -- Corundum Convergence Institute (CCI), a non-profit supporting cutting-edge research at the intersection of neuroscience and systems biology, today announced it has awarded a research grant to Dr. Laura Lewis at the Massachusetts Institute of Technology's Institute for Medical Engineering and Science (IMES).

The project explores the development of algorithms to enhance cerebrospinal fluid (CSF) flow in aging brains. It leverages advanced sensory stimulation techniques to optimize CSF flow during sleep, a state critical for clearing toxic metabolites from the brain and supporting neural health. The study offers potential breakthroughs in the early detection and mitigation of neurodegenerative diseases.

"There is substantial evidence that disordered CSF flow is linked to neurodegeneration. It is therefore critically important to identify interventions that can enhance flow," said Dr. Lewis, Athinoula A. Martinos Associate Professor of IMES and Electrical Engineering and Computer Science, MIT. "Our work will help identify non-invasive, personalized interventions that can improve brain health before the onset of neurodegenerative symptoms."

The study will evaluate a closed-loop sensory stimulation algorithm that increases CSF flow during sleep. Flow is dramatically increased during certain phases of sleep, and sleep loss in midlife may be associated with the onset of neurodegenerative disorders, including Alzheimer's disease. Identifying interventions that can target and improve CSF flow during sleep may be a route to protecting memory and other diseases connected to neurodegeneration.

Dr. Lewis's team has developed algorithms which they have shown to increase CSF flow in younger adults and the CCI-funded study is designed to adapt and extend this to older adults. This work will identify how sensory stimulation during sleep can optimally increase CSF flow across the lifespan, laying a foundation for personalized interventions that prevent neurodegeneration.

"Dr. Lewis's research brings critical focus to the role of cerebrospinal fluid dynamics in aging – a field poised for significant breakthroughs," said Caleb B. Bell III, PhD, President and Executive Director of CCI. "By leveraging the unique physiology of sleep to enhance fluid flow, this work exemplifies the innovative science CCI aims to support – work that not only deepens our understanding of brain aging and neurodegeneration but paves the way for transformative interventions."

"This study is part of a paradigm shift toward understanding and modulating the brain environment in order to address pathological brain states and help promote neural resilience," said Josh Schulman, PhD, Chief Operating Officer for CCI and Chief Scientist for Corundum Neuroscience. "We believe it will contribute to a framework for personalized interventions designed to prevent or delay the onset of disease and support brain function across individuals' lifespans."   

About Corundum Convergence Institute (CCI)
Corundum Convergence Institute (CCI) is a non-profit organization committed to advancing transformative research at the frontiers of neuroscience, systems biology, and artificial intelligence. By focusing on early-stage innovation in complex, high-impact fields, CCI supports the development of products and technologies leading to paradigm shifts in healthcare, including novel therapeutic approaches to neuro-inspired AI and improved diagnostics for neurodegenerative and metabolic conditions. CCI's multidisciplinary approach fosters convergence across fields, enabling scientists and entrepreneurs to explore the intersections of science, human biology and advanced technology in ways that will fundamentally reshape health and wellbeing. CCI is an independently governed entity created by fellow Corundum Corp venture builders and funds Corundum Neuroscience and Corundum Systems Biology. As part of the greater Corundum network, CCI offers a creative path to translate bold scientific ideas to real-world impact.

For company updates and information, follow the Corundum Convergence Institute on LinkedIn or visit https://cci-fund.org/.

Media Contact:
Danny Sudwarts
FINN Partners for Corundum
[email protected]    

SOURCE Corundum Convergence Institute

Modal title

Also from this source

Corundum Convergence Institute and the University of Tokyo's International Research Center for Neurointelligence Launch Inaugural Neuroscience Entrepreneurship Workshop

Corundum Convergence Institute (CCI), a non-profit venture fueling groundbreaking research at the intersection of neuroscience and systems biology,...

Corundum Convergence Institute Awards Research Grant for Novel Use of Brain Stimulation Technique to Combat Fatigue and Enhance Brain Function During Sleep

Corundum Convergence Institute (CCI), a non-profit venture fueling groundbreaking research at the intersection of neuroscience and systems biology,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

STEM (Science, Tech, Engineering, Math)

STEM (Science, Tech, Engineering, Math)

Not For Profit

Not For Profit

News Releases in Similar Topics

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.